REVEAL GENOMICS focuses on advancing precision oncology through innovative genomic testing technologies. Their flagship product, HER2DX®, is designed specifically for patients with HER2+ breast cancer, aiding in the selection of optimal treatment strategies. This genomic tool analyzes complex genomic and clinical data to provide insights that can significantly influence treatment decisions. Additionally, the company has developed TNBCDX®, the first genomic test tailored for early-stage triple-negative breast cancer, which aims to enhance the understanding and management of this challenging cancer type.

The approach taken by REVEAL GENOMICS emphasizes the importance of biomarkers in oncology, striving to redefine their routine use in clinical settings. By decoding biomarkers at various stages of therapy through biopsy-based methods, the company seeks to unlock the full potential of patient information. Their tests are characterized by high analytical complexity yet are designed to yield results that are easy to interpret, thereby facilitating better clinical decision-making and improving patient outcomes.

Spain

Our aim is to develop tests that make use the full power of the complete genetic and clinical information of each patient

REVEAL GENOMICS

Company Details